Aletra Capital Partners

Aletra Capital Partners is the Netherlands-based private equity firm operating from Laren since 2005, and the firm sits in a quieter corner of European healthcare investing than the larger London and Frankfurt names. Aletra invests in B2B enterprise software and medical technology companies with annual recurring revenue above $1 million, focusing on the Netherlands and Singapore as its primary geographies. The firm is a growth and lower-mid-market private equity investor rather than a venture fund, and it brings a different posture to healthcare deals than the venture capital ecosystem. For founders running profitable or near-profitable European healthcare software and medtech businesses, Aletra is one of a small number of specialist partners in their geography.

The thesis is focused on B2B enterprise software and medical technology businesses with established commercial traction, with the firm targeting companies that have crossed the $1 million ARR threshold and have a credible path to growth and profitability. Within medical devices and MedTech and health IT and healthcare software, Aletra invests at Series A, Series B, and growth stages, which positions the firm to participate in growth equity rounds and lower-mid-market buyouts. The firm’s preference is for companies with recurring revenue, defensible product positions, and credible unit economics, and the firm tends to avoid pre-revenue technical bets and consumer healthcare brands. Founders should expect a partner whose first questions are about ARR, gross margin, customer cohorts, and operating leverage rather than about narrative and TAM.

The firm’s portfolio reflects its specialist focus on European and Singapore-based healthcare software and medtech, with investments in companies that have crossed the commercial threshold and are scaling within their home markets or expanding regionally. The pattern is companies with established product-market fit, credible management teams, and growth strategies that emphasize commercial execution rather than further technology development. Aletra is not a turnaround investor, and the firm is not built to participate in distressed situations; the focus is on healthy growth-stage companies that need a private equity-style partner to professionalize operations and accelerate expansion.

Check sizes are in the $5 million to $25 million range at Series A, Series B, and growth, with the firm comfortable participating in both minority growth investments and majority transactions depending on the situation. The capital stack positioning is that of a European specialist private equity investor who can lead growth rounds and execute lower-mid-market buyouts, with a particular comfort in the Netherlands and Singapore. Founders raising a Series B or growth round on healthy unit economics will find Aletra a credible lead. Founders raising venture-style rounds without commercial traction will find the conversation does not move forward.

The team operates from Laren in the Netherlands and brings a combination of private equity, healthcare operating, and European market experience. Decision-making follows a private equity model with investment committee oversight, detailed commercial diligence, and operating-team interviews. Founders should expect a slower process than a typical venture financing but a more substantive operating partnership at the end of it. The firm’s communication style is direct and operationally focused, with a particular emphasis on financial discipline and commercial execution.

The most reliable path into Aletra is a warm introduction from a portfolio CEO, a European healthcare investment banker, or a senior operator in the Netherlands or Singapore healthcare ecosystem. Introductions from European technology and healthcare advisors who have transacted with the firm are particularly effective. Cold outreach from credible commercial-stage European healthcare software and medtech companies is read and converted at a reasonable rate, given the firm’s narrower geographic and stage focus. Communication after first contact is structured and professional.

Approach Aletra when you are running a European or Singapore-based B2B healthcare software or medtech company with established ARR and a credible growth strategy, and when you are open to a private-equity-style partnership that includes operational engagement. Do not approach when you are pre-revenue, when you are running a US-focused venture process, or when you need a brand-forward consumer investor. Aletra is a focused, European specialist growth and buyout partner for healthcare technology founders who have already proven the commercial thesis and need the right kind of capital to compound from there.